Navigation Links
Inspiration Biopharmaceuticals Announces Filing of IND for Novel Recombinant Factor IX Product, IB1001, for the Treatment of Hemophilia B
Date:11/13/2007

LAGUNA NIGUEL, Calif., Nov. 13 /PRNewswire/ -- Inspiration Biopharmaceuticals announced today that it has filed an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) to begin clinical trials with IB1001, an intravenous recombinant Factor IX (rFIX) product for the on demand and prophylactic treatment of the bleeding disorder associated with hemophilia B.

Upon FDA approval of the IND application, Inspiration Biopharmaceuticals intends to enter Phase 1/2 clinical trials to evaluate the pharmacokinetics (PK) and safety profile of IB1001, compared with the commercially available Factor IX products; rFIX, BeneFix(R) and plasma-derived Factor, MonoNine(R). Following successful completion of the PK phase of this study, patients will then enroll in one of two trials: a six month Phase 1/2 On Demand trial to document safety and efficacy in treating spontaneous bleeding episodes or a pivotal Phase 2/3 Prophylaxis trial to document safety and efficacy in the prevention of spontaneous bleeding. In addition, the safety and efficacy of peri-surgical prophylactic administration of IB1001 to control bleeding during surgical procedures will be evaluated. The rate of inhibitor formation will be evaluated throughout all phases of the clinical investigation of IB1001.

"We are excited to be filing an IND for IB1001," said Michael Griffith, Ph.D., President and CEO, Inspiration Biopharmaceuticals. "Preclinical studies have demonstrated the expected PK and safety profile for IB1001 when compared to the clinically proven commercial Factor IX products. Our cost-effective manufacturing platform for Factor IX positions Inspiration to expand the global supply of i.v. rFIX and to develop next generation products to facilitate prophylactic care of the hemophilia B patients worldwide. Our ultimate goal is to leverage our low cost manufacturing technology to find the means for non-invasive delivery of Factor IX which we believe may represe
'/>"/>

SOURCE Inspiration Biopharmaceuticals
Copyright©2007 PR Newswire.
All rights reserved

3

GOOD

Page: 1 2 3

Related medicine technology :

1. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
2. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
3. Nabi Biopharmaceuticals Announces Continued Positive NicVAX Phase 2b Data at Nine Months
4. Keryx Biopharmaceuticals to Present at William Blair & Company Small-Cap Growth Stock Conference
5. Morria Biopharmaceuticals Plc Initiates Phase I Clinical Study of MRX-4 in Allergic Rhinitis
6. Keryx Biopharmaceuticals, Inc. Announces Positive Preliminary Phase 2 Data on KRX-0401 in Patients with Chemo-Insensitive Rare Sarcoma
7. Nabi Biopharmaceuticals Announces Successful Completion of NicVAX(R) Phase 2b Trial; Drug Shows Statistically Significant Rates of Smoking Cessation and Continuous Long-Term Smoking Abstinence at 12 Months
8. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
9. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
10. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
11. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2008)...o take body temperature, for home,and clinical use...- Kidz-Med, Inc.,(subsidiary of American Scientifi... distributor of the Thermofocus(R) 5-in-1 non-cont...s of a clinical study,conducted by the Second Chil..., Italy, which proves that the Thermofocus(R) meas...
(Date:7/23/2008)... Therapy to Treat the Disease -, WAYNE, N.J. and ... --,Bayer HealthCare Pharmaceuticals and Onyx Phar...hat The New England Journal of Medicine published,...var(R) (sorafenib),tablets decreased the absolute ...ectable hepatocellular carcinoma (HCC), or liver c...
(Date:7/23/2008)...wswire/ -- The following was,released by the U.S. ... Member Smith, and Members of the Committee.,Thank... I appeared before this Committee almost six month...he talented and dedicated professionals,at the Jus...ave come to,appreciate that much more deeply their...
(Date:7/23/2008)...-- InCode BioPharmaceutics, Inc.,an emerging biop... test,results demonstrating the utility of their l...rare chronic blood disorder paroxysmal nocturnal,h...presented at the XXII,International Complement Wor... The only treatment currently available for PNH pa...
Breaking Medicine Technology:Pediatric Study Finds 21st Century Non-Contact Thermometer as Accurate as Conventional Thermometers 2The New England Journal of Medicine Publishes Nexavar(R) Study Demonstrating Significant Improvement in Overall Survival in Patients With Liver Cancer 2The New England Journal of Medicine Publishes Nexavar(R) Study Demonstrating Significant Improvement in Overall Survival in Patients With Liver Cancer 3The New England Journal of Medicine Publishes Nexavar(R) Study Demonstrating Significant Improvement in Overall Survival in Patients With Liver Cancer 4The New England Journal of Medicine Publishes Nexavar(R) Study Demonstrating Significant Improvement in Overall Survival in Patients With Liver Cancer 5The New England Journal of Medicine Publishes Nexavar(R) Study Demonstrating Significant Improvement in Overall Survival in Patients With Liver Cancer 6Prepared Remarks of Attorney General Michael B. Mukasey Before the House Judiciary Committee 2Prepared Remarks of Attorney General Michael B. Mukasey Before the House Judiciary Committee 3InCode BioPharmaceutics, Inc. Announces Key Data Supporting New Treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH) 2Pharsight to Present on IVIVC at Bioequivalence 26 Bioavailability Strategies Conference 6142 1Pharsight to Present on IVIVC at Bioequivalence 26 Bioavailability Strategies Conference 6142 2Pharsight to Present on IVIVC at Bioequivalence 26 Bioavailability Strategies Conference 6142 3Immune Design Announces 2418 Million Series A Financing 22475 1Immune Design Announces 2418 Million Series A Financing 22475 2Immune Design Announces 2418 Million Series A Financing 22475 3John 26 Jean Piety Named SLA Engineering Librarians of the Year 22473 1John 26 Jean Piety Named SLA Engineering Librarians of the Year 22473 2Chiltern Enhances Its Portfolio of Electronic Data Capture 28EDC 29 Services With the Addition of Hosting and eCRF Design Services for DataLabs 28by 22470 1Chiltern Enhances Its Portfolio of Electronic Data Capture 28EDC 29 Services With the Addition of Hosting and eCRF Design Services for DataLabs 28by 22470 2
...tionality in Humans of CTI,s,Programmable, Pulsati...onoDose, BASEL, Switzerland and TRENTON, N.J., May... (CTI) announced today the successful,completion o...rammable, pulsatile, passive transdermal drug/devi...s to publish this,clinical data in leading scienti...
...IRE)--May 7, 2007 - NanoViricides,Inc. (Pink Shee...es,against rabies and BSL3 in vitro studies agains...rd Annual Symposium of the Pan,American Society fo...y 2. (Pan American Society for Clinical Virology (...dies against Clade 2 H5N1, a Dec. 2006 isolate in,...
Other Medicine Technology:Successful Human Clinical Trial of Chrono Therapeutic's Drug/Device,Combination Product - ChronoDose 2Successful Human Clinical Trial of Chrono Therapeutic's Drug/Device,Combination Product - ChronoDose 3NanoViricides Drugs Found To Be Highly Effective Against Most,Recent Strain of the H5N1 Avian Flu Virus 2
(Date:7/25/2008)...er Releases Results of Fourth Annual Physician On-...DETROIT, July 25 /PRNewswire/ -- Sullivan, Cotter ...al survey of physician on-call pay rates and,pract.... The survey report,with data from 132 healthcare...all pay practices and rates paid for 33 physician ...
(Date:7/25/2008)...ionship Based on Significant Improvements in Membe...tacor, Inc., a leader in health,care quality manag...day,announced it has entered into a long-term agre...ellmark,s Collaboration on Quality(SM) Incent and,...between Wellmark and,primary care clinicians to pr...
(Date:7/25/2008)...ly 25 /PRNewswire/ -- The Elekta Family of Compani...ment solutions at the 2008,American Association of...onstrating how the joint forces of Elekta, IMPAC a...py planning and delivery solutions that,streamline...ce for,patients, as well as enhance clinician effi...
(Date:7/25/2008)...id back-up in esophagus can cause immune system ch...s) -- The first evidence linking gastroesophageal ...ed by Duke University Medical Center researchers. ... first noted in the 1970s, and since then studies ...of asthma patients also experience GERD symptoms. ...
Breaking Medicine News(10 mins):Health News:Hospital Expenditures for Physician On-Call Pay Rates Nearly Double 2Health News:Hospital Expenditures for Physician On-Call Pay Rates Nearly Double 3Health News:MDdatacor Extends Contract with Wellmark, Inc. 2Health News:MDdatacor Extends Contract with Wellmark, Inc. 3Health News:Elekta Family of Companies to Highlight Cancer Treatment Solutions at 2008 AAPM Annual Meeting 2Health News:Elekta Family of Companies to Highlight Cancer Treatment Solutions at 2008 AAPM Annual Meeting 3Health News:People With GERD More Likely to Develop Asthma 2
...the risk of heart disease, but now researchers say...r the development of a heart attack.This is becaus... almost immediate impact on the cardiovascular sys...ents, the researchers found that those who smoked ...
...chool of Medicine have recently found that the bra...hat lets us stop smelling something, even though t... recent issue of the journal Science show that a p...‘nose’ of odour receptor cells.//The main job of t...
...inking could reduce their risk of suffering a stro.... In a new leaflet, the Stroke Association says sm...ic strokes - caused by blood clots blocking arteri...es of the brain attack.// Alcohol thins the blood...
...he South Sea Islands. It is a herb that has been i...ses. The herb is commonly used by consumers as a g...ress and muscle spasms. According to experts, the ...wn as// benzodiazepines but is not chemically rela...
Other Medicine News:
The Sphincter of Oddi Manometry Application for POLYGRAM NET™ (PNET) works with the Polygraf™ ID multiparametric recorder to record and analyze pressure signals from sphincter of Oddi man
...rise the SmartPill GI Monitoring System., ,Three ...toring System: SmartPill pH.p Capsule software, Sm...iGI software. These three components are integrate...toring System and function together with system ha...
... NET™ (PNET) works with the Polygraf™ ...pressure signals from continuous pull-through proc...cter (LES)., ,Continuous pull-through procedures ...r Puller, but they may be carried out manually wit...
... POLYGRAM NET™ works with the Polygraf&trade...e multichannel EGG signals. The EGG analysis takes...ng an automatic electrode impedance check on every...ording. If the electrode impedance is measured abo...
Medicine Products: